Federal
Register Notices > Manufacturers 2008
>
Mallinckrodt Inc.
FR Doc E8-5528[Federal Register: March 19, 2008 (Volume 73, Number 54)]
[Notices] [Page 14840-14841] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19mr08-88]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec.
1301.33(a) of Title 21 of the Code of Federal Regulations (CFR),
this is notice that on November 30, 2007, Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
Drug
|
Schedule
|
Tetrahydrocannabinols (7370)
|
I
|
Codeine-N-oxide (9053)
|
I
|
Dihydromorphine (9145)
|
I
|
Difenoxin (9168)
|
I
|
Morphine-N-oxide (9307)
|
I
|
Normorphine (9313)
|
I
|
Norlevorphanol (9634)
|
I
|
Amphetamine (1100)
|
II
|
Methamphetamine (1105)
|
II
|
Methylphenidate (1724)
|
II
|
Nabilone (7379)
|
II
|
Codeine (9050)
|
II
|
Diprenorphine (9058)
|
II
|
Etorphine HCL (9059)
|
II
|
Dihydrocodeine (9120)
|
II
|
Oxycodone (9143)
|
II
|
Hydromorphone (9150)
|
II
|
Diphenoxylate (9170)
|
II
|
Ecgonine (9180)
|
II
|
Hydrocodone (9193)
|
II
|
Levorphanol (9220)
|
II
|
Meperidine (9230)
|
II
|
Methadone (9250)
|
II
|
Methadone intermediate (9254)
|
II
|
Metopon (9260)
|
II
|
Dextropropoxyphene, bulk (9273)
|
II
|
Morphine (9300)
|
II
|
Thebaine (9333)
|
II
|
Opium extracts (9610)
|
II
|
Opium fluid extract (9620)
|
II
|
Opium tincture (9630)
|
II
|
Opium, powdered (9639)
|
II
|
Opium, granulated (9640)
|
II
|
Levo-alphacetylmethadol (9648)
|
II
|
Oxymorphone (9652)
|
II
|
Noroxymorphone (9668)
|
II
|
Phenazocine (9715)
|
II
|
Alfentanil (9737)
|
II
|
Remifentanil (9739)
|
II
|
Sufentanil (9740)
|
II
|
Fentanyl (9801)
|
II
|
The firm plans to manufacture the listed controlled substances for internal
use and for sale to other companies.
Any other such applicant and any person who is presently registered with DEA
to manufacture such substances may file comments or objections to the issuance
of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such written comments or objections being sent via regular mail
[[Page 14841]]
should be addressed, in quintuplicate, to the Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent to Drug
Enforcement Administration, Office of Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette Drive, Springfield, VA. 22152; and must
be filed no later than May 19, 2008.
Dated: March 10, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-5528 Filed 3-18-08; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|